Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first-in-human study and during experimental human endotoxaemia in healthy subjects

There is no fulltext present in this item.

Title:	Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first-in-human study and during experimental human endotoxaemia in healthy subjects
Author(s):	Geven, C.B.C.A.G.; Lier, Dirk van; Blet, A.; Peelen, R.V. ; Elzen, Bas ten; Mebazaa, Alexandre; Kox, M. ; Pickkers, P.
Publication year:	2018
Source:	British Journal of Clinical Pharmacology, vol. 84, iss. 9, (2018), pp. 2129-2141
ISSN:	0306-5251
DOI:	https://doi.org/10.1111/bcp.13655
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : http://hdl.handle.net/2066/194891
Display more details
Subject:	All institutes and research themes of the Radboud University Medical Center Radboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life Sciences
Organization:	Intensive Care Internal Medicine
Journal title:	British Journal of Clinical Pharmacology
Volume:	vol. 84
Issue:	iss. 9
Page start:	p. 2129
Page end:	p. 2141